Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome

Authors: Florentin, M.; Elisaf, M. S.; Mikhailidis, D. P.; Liberopoulos, E. N.

Source: Current Pharmaceutical Design, Volume 15, Number 29, October 2009 , pp. 3446-3462(17)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially combinations of different drugs, in order to tackle all the features of MetS. We review the therapeutic strategies currently used for obesity and dyslipidemia treatment in patients with MetS, with a focus on drug combinations.

Keywords: Bile acid sequestrants; ezetimibe; fibrates; metabolic syndrome; niacin; orlistat; rimonabant; statins

Document Type: Research article

Affiliations: 1: Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital,Royal Free and University College School of Medicine, Pond Street, London NW3 2QG, UK.

Publication date: 2009-10-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.